WANDA CAESAR: Open Payments
NPI 1316288699 · BETHESDA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,002 in 77 payments from 11 companies in 2025. Trend: 2023 $839 · 2024 $564 · 2025 $2,002
Food & beverage: $2,002
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $385 |
| E.R. Squibb & Sons, L.L.C. | 14 | $290 |
| Alkermes, Inc. | 14 | $248 |
| Janssen Pharmaceuticals, Inc | 6 | $247 |
| Neurocrine BioSciences, Inc. | 8 | $206 |
| Otsuka America Pharmaceutical, Inc. | 8 | $189 |
| bioMerieux Inc | 1 | $162 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Lundbeck LLC | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
Products named: FANAPT, COBENFY, ARISTADA, INVEGA SUSTENNA, INGREZZA, ABILIFY ASIMTUFII, REXULTI, HETLIOZ.
Industry payments across MD — which companies pay providers there.
